What is HC Wainwright’s Estimate for AURA Q1 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright issued their Q1 2026 earnings estimates for shares of Aura Biosciences in a report issued on Thursday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the company will earn ($0.44) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.45) EPS.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Thursday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06.

Several other equities research analysts have also recently commented on AURA. Zacks Research raised Aura Biosciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Aura Biosciences has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Aura Biosciences Price Performance

AURA stock opened at $5.41 on Monday. The company has a 50 day moving average price of $5.97 and a 200 day moving average price of $6.22. Aura Biosciences has a fifty-two week low of $4.34 and a fifty-two week high of $9.53. The stock has a market capitalization of $343.54 million, a PE ratio of -2.79 and a beta of 0.45.

Insiders Place Their Bets

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 9,049 shares of Aura Biosciences stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $6.35, for a total transaction of $57,461.15. Following the transaction, the insider directly owned 474,391 shares in the company, valued at approximately $3,012,382.85. The trade was a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Mark Plavsic sold 12,169 shares of the stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $6.35, for a total value of $77,273.15. Following the completion of the sale, the chief technology officer owned 197,287 shares of the company’s stock, valued at $1,252,772.45. This trade represents a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 39,223 shares of company stock worth $233,155. Corporate insiders own 6.30% of the company’s stock.

Institutional Trading of Aura Biosciences

Several hedge funds have recently bought and sold shares of AURA. Frazier Life Sciences Management L.P. acquired a new position in shares of Aura Biosciences in the second quarter valued at approximately $31,926,000. Long Focus Capital Management LLC boosted its stake in Aura Biosciences by 30.8% in the 1st quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company’s stock worth $19,453,000 after purchasing an additional 781,808 shares during the period. Vanguard Group Inc. boosted its stake in Aura Biosciences by 16.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company’s stock worth $17,863,000 after purchasing an additional 413,001 shares during the period. Franklin Resources Inc. increased its holdings in Aura Biosciences by 5.9% during the 2nd quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock worth $14,653,000 after purchasing an additional 130,221 shares in the last quarter. Finally, Nantahala Capital Management LLC raised its stake in shares of Aura Biosciences by 67.1% in the 2nd quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company’s stock valued at $13,257,000 after purchasing an additional 850,000 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.